ArticleAdvances in experimental medicine and biology2021
Progressive Supranuclear Palsy and Corticobasal Degeneration.
Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Comorbid pathologies and their impact on progressive supranuclear palsy: current view.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Tau conformation, distribution and PET imaging correlations in progressive supranuclear palsy.Translational neurodegeneration · 2026Review
- Predictive value of cerebrospinal fluid Alzheimer's disease biomarkers and neuropsychological measures for cognitive and motor outcomes in Parkinson's disease.Brain communications · 2026Article
- Combining plasma biomarkers, clinical parameters, and neuroimaging features for differential diagnosis of Parkinson's disease and atypical parkinsonian syndromes: a multidimensional modeling approach.Frontiers in aging neuroscience · 2026Article
- Cognitive and neuropsychiatric profiles distinguish atypical parkinsonian syndromes.Brain : a journal of neurology · 2025Article
- Alzheimer's Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective.International journal of molecular sciences · 2025Review
- Pathomechanisms of neuropsychiatric disturbances in atypical parkinsonian disorders: a current view.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- The Spectrum of Cognitive Impairment in Atypical Parkinsonism Syndromes: A Comprehensive Review of Current Understanding and Research.Diseases (Basel, Switzerland) · 2025Review
- Review
- Pathomechanisms of cognitive and behavioral impairment in corticobasal degeneration.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- The therapeutic landscape of tauopathies: challenges and prospects.Alzheimer's research & therapy · 2023Review
- Pathomechanisms of depression in progressive supranuclear palsy.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- New Approaches to the Treatment of Frontotemporal Dementia.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- Pathomechanisms of cognitive impairment in progressive supranuclear palsy.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Caspase-6-cleaved tau is relevant in Alzheimer's disease and marginal in four-repeat tauopathies: Diagnostic and therapeutic implications.Neuropathology and applied neurobiology · 2022Article
- Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies.Brain communications · 2022Article
- Structure-based classification of tauopathies.Nature · 2021Article
- Patterns of neuronal Rhes as a novel hallmark of tauopathies.Acta neuropathologica · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neurodegenerative tauopathies with neuronal and glial lesions composed of tau that is composed predominantly of isomers with four repeats in the microtubule-binding domain (4R tau). The brain regions vulnerable to pathology in PSP and CBD overlap, but there are differences, particularly with respect to distribution of neuronal loss, the relative abundance of neuronal and glial lesions, the morphologic features of glial lesions, and the frequency of comorbid pathology. Both PSP and CBD have a wide spectrum of clinical manifestations, including disorders of movement and cognition. Recognition of phenotypic diversity in PSP and CBD may improve antemortem diagnostic accuracy, which tends to be very good for the most common presentation of PSP (Richardson syndrome), but poor for the most characteristic presentation of CBD (corticobasal syndrome: CBS). Development of molecular and imaging biomarkers may improve antemortem diagnostic accuracy. Currently, multidisciplinary symptomatic and supportive treatment with pharmacological and non-pharmacological strategies remains the standard of care. In the future, experimental therapeutic trials will be important to slow disease progression.
Indexed as
Identifiers
33433875What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.